Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Regulatory News (PRM)

Share Price Information for Proteome (PRM)

Share Price is delayed by 15 minutes
Get Live Data
1.60    0.00 (0.00%)
Bid:
1.60
Ask:
2.00
Spread: 0.40 (25.00%)
Market Cap: £5.61m
PRM Live PriceLast checked at - London Stock Exchange

Intraday Proteome Share Chart

Directorate Change

30 Sep 2014 07:00

RNS Number : 9286S
Proteome Sciences PLC
30 September 2014
 



 

 

 

 

 

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Appointment of new Finance Director

 

30th September, 2014 - The Board of Proteome Sciences is pleased to announce the appointment of Mr. Geoffrey Ellis as Finance Director with effect from 1st October. Mr. Geoffrey John Ellis, 53, is a chartered accountant with over 30 years' experience in a range of senior financial, operational, sales and business development roles. He spent 15 years at Walt Disney where he was Chief Financial Officer of the Network of Disney Channels in EMEA and Managing Director of Disney Chanel Scandinavia, Middle East and Emerging Markets.

In addition to a strong financial background, he brings considerable international sales, marketing and licensing expertise and a key part of his role will be managing and expanding our commercial sales and marketing in USA and Europe.

Mr. James Malthouse will remain as a director of the company until his retirement on 30th November, 2014.

Mr. Ellis was a director of Curzon ISC Limited until shortly before it was placed into voluntary liquidation in March 2011. He was also a director of Warren Close Residents Association (Esher) Limited at the time it was placed into voluntary liquidation in May 2013.

Other than disclosed above, the Company confirms that there is no further information required to be disclosed in accordance with paragraph (g) of Schedule 2 of the AIM Rules.

 

- Ends -

For further information please contact:

Proteome Sciences plc

Christopher Pearce, Executive Chairman

Dr. Ian Pike, Chief Operating Officer Tel: +44 (0)1932 865065

James Malthouse, Finance Director

 

Cenkos - Nominated Adviser

Stephen Keys/Mark Connelly /Callum Davidson Tel: +44 (0)20 7397 8900

 

finnCap - Joint Broker

Geoff Nash (Corporate Finance) Tel: +44 (0)20 7220 0500

Tony Quirke (Broking)

 

IKON Associates - Public Relations

Adrian Shaw Tel: +44 (0)1483 271291

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAVKLFLZKFFBBX
Date   Source Headline
12th Nov 20147:00 amRNSTrading Update
16th Oct 20147:00 amRNSDirectorate Change
1st Oct 20143:54 pmRNSDirector/PDMR Shareholding
30th Sep 20147:01 amRNSBlocklisting Interim Review
30th Sep 20147:00 amRNSDirectorate Change
30th Sep 20147:00 amRNSHalf Yearly Report
26th Sep 20147:00 amRNSCK1d Update: Toxicity Results
25th Sep 201410:08 amRNSContract with Genting TauRx Diagnostic Centre
15th Sep 20147:00 amRNSScience and Technology Award
19th Aug 20147:00 amRNSAppointment of Joint Broker
8th Jul 20145:45 pmRNSDirector/PDMR Shareholding
8th Jul 20147:00 amRNSAlzheimer's blood test study
1st Jul 20147:00 amRNSDirectorate Change
30th Jun 20144:42 pmRNSResult of AGM
9th Jun 20144:18 pmRNSAnnual Financial Report
29th May 20147:00 amRNSPreliminary results
1st Apr 20147:00 amRNSBlocklisting Interim Review
27th Mar 20147:00 amRNSPancreatic Cancer Study in PLOS ONE
3rd Mar 20144:25 pmRNSDirectorate Change
28th Feb 20143:46 pmRNSHolding(s) in Company
24th Feb 20147:00 amRNSPlacing
7th Feb 20147:00 amRNSTrading Update
3rd Feb 20144:44 pmRNSHolding(s) in Company
27th Dec 20134:35 pmRNSPrice Monitoring Extension
4th Dec 20137:00 amRNSTrading Update
20th Nov 20137:00 amRNSPatient Stratification Biomarkers for Liver Cancer
6th Nov 20132:51 pmRNSHolding(s) in Company
1st Oct 201310:34 amRNSBlocklisting Interim Review
30th Sep 20137:00 amRNSHalf Yearly Report
18th Sep 20132:00 pmRNSKey Assay Development at HUPO
2nd Sep 201312:12 pmRNSHolding(s) in Company
6th Aug 201312:36 pmRNSIssue of Equity
18th Jul 20137:00 amRNSNew Data Shows CK1d Blocks Tau in AD Model
28th Jun 20131:00 pmRNSAGM Statement
28th Jun 20137:00 amRNSPatent Statement
26th Jun 20139:27 amRNSHolding(s) in Company
12th Jun 20137:00 amRNSMajor technology contract
5th Jun 20134:08 pmRNSAnnual Financial Report
30th May 20137:01 amRNSPreliminary Results
19th Apr 20137:00 amRNSTrading Update
2nd Apr 20137:00 amRNSBlock admission return
18th Mar 20137:00 amRNSDevelopments in Alzheimer's Disease
22nd Jan 20137:00 amRNSTrading Statement
31st Dec 20127:00 amRNSCK1D Update
3rd Dec 201211:06 amRNSHolding(s) in Company
28th Sep 20127:00 amRNSHalf Yearly Report
18th Sep 20124:04 pmRNSBlock Admission Return
18th Sep 20124:01 pmRNSBlock Admission Return
18th Sep 20127:00 amRNSFurther re. University of Geneva Study
20th Aug 20127:00 amRNSRe Agreement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.